Attached files

file filename
EX-10.10 - MASTER SERVICES AGREEMENT, DATED FEBRUARY 8, 2021, BY AND BETWEEN UNICYCIVE THER - Unicycive Therapeutics, Inc.ea141453ex10-10_unicycive.htm
EX-10.9 - AMENDMENT TO EMPLOYMENT AGREEMENT BY AND BETWEEN THE COMPANY AND PRAMOD GUPTA, M - Unicycive Therapeutics, Inc.ea141453ex10-9_unicycive.htm
EX-10.8 - EMPLOYMENT AGREEMENT BY AND BETWEEN THE COMPANY AND PRAMOD GUPTA, M.D., DATED MA - Unicycive Therapeutics, Inc.ea141453ex10-8_unicycive.htm
EX-10.7 - EMPLOYMENT AGREEMENT BY AND BETWEEN THE COMPANY AND SHALABH GUPTA, M.D., DATED M - Unicycive Therapeutics, Inc.ea141453ex10-7_unicycive.htm
EX-10.3 - 2021 OMNIBUS EQUITY INCENTIVE PLAN - Unicycive Therapeutics, Inc.ea141453ex10-3_unicycive.htm
EX-4.1 - SPECIMEN STOCK CERTIFICATE EVIDENCING THE SHARES OF COMMON STOCK - Unicycive Therapeutics, Inc.ea141453ex4-1_unicycive.htm
EX-3.5 - FORM OF AMENDED AND RESTATED BYLAWS, TO BE EFFECTIVE IMMEDIATELY PRIOR TO THE EF - Unicycive Therapeutics, Inc.ea141453ex3-5_unicycive.htm
EX-3.4 - FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO BE EFFECTIVE IMMED - Unicycive Therapeutics, Inc.ea141453ex3-4_unicycive.htm
S-1 - REGISTRATION STATEMENT - Unicycive Therapeutics, Inc.ea141453-s1_unicycive.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the inclusion in this Registration Statement on Form S-1 of our report dated February 18, 2021, with respect to the financial statements of Unicycive Therapeutics, Inc. as of December 31, 2020 and 2019, and for the years then ended (which includes an explanatory paragraph related to the existence of substantial doubt about the Company’s ability to continue as a going concern), and to the reference to us under the heading “Experts” included in this Registration Statement and accompanying prospectus on Form S-1.

 

/s/ Mayer Hoffman McCann P.C.

San Diego, California

May 21, 2021